血液透析合并2型糖尿病患者中类似物胰岛素与人胰岛素的结局比较
本研究为回顾性队列研究,纳入AROii研究中2007-2009年7个欧洲国家288家透析中心的713例类似物胰岛素使用者和733例人胰岛素使用者,随访3年。相比人胰岛素,类似物胰岛素与更低的全因死亡、MACE和住院风险相关,低血糖发生率两组相当。
要点
- 3年全因死亡率类似物组22.0% vs 人胰岛素组31.4%(AHR 0.808,95%CI 0.66-0.99,P=0.04)。
- 3年MACE发生率类似物组26.8% vs 人胰岛素组35.9%(AHR 0.817,95%CI 0.68-0.98,P=0.03)。
- 3年住院率类似物组58.2% vs 人胰岛素组75.0%(AHR 0.757,95%CI 0.67-0.86,P<0.001);低血糖两组相当(14.1% vs 15.0%,AHR 1.169,95%CI 0.80-1.72,P=0.4)。
核心结论
- 在接受维持性血液透析的2型糖尿病合并肾衰竭患者中,与人胰岛素相比,类似物胰岛素治疗与更好的临床结局相关。
研究设计与样本
- 回顾性队列研究,纳入AROii研究中2007-2009年7个欧洲国家288家透析机构的713例类似物胰岛素使用者和733例人胰岛素使用者,随访3年。
主要发现
- 3年全因死亡率类似物组22.0% vs 人胰岛素组31.4%(AHR 0.808,95%CI 0.66-0.99,P=0.04)。
- 3年MACE发生率类似物组26.8% vs 人胰岛素组35.9%(AHR 0.817,95%CI 0.68-0.98,P=0.03)。
- 3年住院率类似物组58.2% vs 人胰岛素组75.0%(AHR 0.757,95%CI 0.67-0.86,P<0.001)。
- 低血糖发生率类似物组14.1% vs 人胰岛素组15.0%(AHR 1.169,95%CI 0.80-1.72,P=0.4)。
关键数值与推荐
- 低血糖定义为透析中采样血糖<3.0mmol/L。
- 采用逆概率加权Cox比例风险模型估计类似物胰岛素相比人胰岛素的风险比。
临床怎么用
- 研究结果提示类似物胰岛素应被进一步探索作为改善透析糖尿病患者结局的治疗选择。
局限性
- 残余混杂。
- 缺乏更详细的血糖数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Poor glycemic control may contribute to the high mortality rate in patients with type 2 diabetes receiving hemodialysis. Insulin type may influence glycemic control, and its choice may be an opportunity to improve outcomes. This study assessed whether treatment with analog insulin compared with human insulin is associated with different outcomes in people with type 2 diabetes and kidney failure receiving hemodialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: People in the Analyzing Data, Recognizing Excellence and Optimizing Outcomes (AROii) study with kidney failure commencing hemodialysis and type 2 diabetes being treated with insulin within 288 dialysis facilities between 2007 and 2009 across 7 European countries. Study participants were followed for 3 years. People with type 1 diabetes were excluded using an established administrative data algorithm. EXPOSURE: Treatment with an insulin analog or human insulin. OUTCOME: All-cause mortality, major adverse cardiovascular events (MACE), all-cause hospitalization, and confirmed hypoglycemia (blood glucose<3.0mmol/L sampled during hemodialysis). ANALYTICAL APPROACH: Inverse probability weighted Cox proportional hazards models to estimate hazard ratios for analog insulin compared with human insulin. RESULTS: There were 713 insulin analog and 733 human insulin users. Significant variation in insulin type by country was observed. Comparing analog with human insulin at 3 years, the percentage of patients experiencing end points and adjusted hazard ratios (AHR) were 22.0% versus 31.4% (AHR, 0.808 [95% CI, 0.66-0.99], P=0.04) for all-cause mortality, 26.8% versus 35.9% (AHR, 0.817 [95% CI, 0.68-0.98], P=0.03) for MACE, and 58.2% versus 75.0% (AHR, 0.757 [95% CI, 0.67-0.86], P<0.001) for hospitalization. Hypoglycemia was comparable between insulin types at 14.1% versus 15.0% (AHR, 1.169 [95% CI, 0.80-1.72], P=0.4). Consistent strength and direction of the associations were observed across sensitivity analyses. LIMITATIONS: Residual confounding, lack of more detailed glycemia data. CONCLUSIONS: In this large multinational cohort of people with type 2 diabetes and kidney failure receiving maintenance hemodialysis, treatment with analog insulins was associated with better clinical outcomes when compared with human insulin. PLAIN-LANGUAGE SUMMARY: People with diabetes who are receiving dialysis for kidney failure are at high risk of cardiovascular disease and death. This study uses information from 1,446 people with kidney failure from 7 European countries who are receiving dialysis, have type 2 diabetes, and are prescribed either insulin identical to that made in the body (human insulin) or insulins with engineered extra features (insulin analog). After 3 years, fewer participants receiving analog insulins had died, had been admitted to the hospital, or had a cardiovascular event (heart attack, stroke, heart failure, or peripheral vascular disease). These findings suggest that analog insulins should be further explored as a treatment leading to better outcomes for people with diabetes on dialysis.
引用
- Ebert T, Sattar N, Greig M, et al. Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia. Am J Kidney Dis. 2023. PMID: 37657634. doi:10.1053/j.ajkd.2023.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。